Novartis: FDA approval in HPN
This approval is based on the APPLY-PNH trial in adults with HPN and anemia despite prior anti-C5 therapy, and is supported by the APPOINT-PNH study in complement inhibitor-naïve patients.
Significant unmet needs remain in HPN; despite anti-C5 treatment, a large proportion of patients may remain anemic and dependent on blood transfusions", stresses the Swiss pharmaceutical company.
Copyright (c) 2023 CercleFinance.com. All rights reserved.